Horizon Therapeutics plc Initiates PROTECT Trial Evaluating KRYSTEXXA (pegloticase injection)
Horizon Therapeutics plc announced it has initiated an open-label clinical trial evaluating the use of KRYSTEXXA (pegloticase injection) in adults with chronic gout refractory to…
Read More...
Read More...
